GLENMARK PHARMA: GUIDANCE

GLENMARK PHARMA: GUIDANCE - CO PROVIDED GUIDANCE FOR FY26, INCLUDING REVENUE GROWTH OF 10% TO 12%, EBITDA MARGIN OF 19% TO 20%, AND CASH GENERATION OF INR300 CRORES TO INR400 CRORES || GUIDANCE FOR EBITDA IS AROUND 19%. - CONCALL UPDATE